tiprankstipranks
Avalo Therapeutics (DE:C6K0)
FRANKFURT:C6K0
Germany Market
C6K0
Avalo Therapeutics
RESEARCH TOOLSreports

Avalo Therapeutics (C6K0) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

C6K0 Analyst Ratings

Strong Buy
10Ratings
Strong Buy
10 Buy
0 Hold
0 Sell
Based on 10 analysts giving stock ratings to
Avalo
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

C6K0 Stock 12 Month Forecast

Average Price Target

€36.84
▲(138.27% Upside)
Based on 10 Wall Street analysts offering 12 month price targets for Avalo Therapeutics in the last 3 months. The average price target is €36.84 with a high forecast of €50.34 and a low forecast of €26.04. The average price target represents a 138.27% change from the last price of €15.46.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"€5","28":"€28","51":"€51","16.5":"€16.5","39.5":"€39.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":50.33704116,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€50.34</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":36.83668529333333,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€36.84</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":26.0364006,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€26.04</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,16.5,28,39.5,51],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.72,19.30592624307692,21.891852486153844,24.47777872923077,27.06370497230769,29.649631215384616,32.23555745846154,34.82148370153846,37.40740994461538,39.99333618769231,42.579262430769234,45.16518867384615,47.75111491692308,{"y":50.33704116,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.72,18.26743733025641,19.81487466051282,21.36231199076923,22.90974932102564,24.45718665128205,26.004623981538458,27.55206131179487,29.09949864205128,30.64693597230769,32.1943733025641,33.74181063282051,35.28924796307692,{"y":36.83668529333333,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.72,17.4366462,18.153292399999998,18.869938599999998,19.5865848,20.303231,21.0198772,21.7365234,22.4531696,23.169815800000002,23.886462,24.6031082,25.3197544,{"y":26.0364006,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.67,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.73,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.56,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.38,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.46,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.54,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.44,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.52,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.76,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.04,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.5,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.94,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.72,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€50.34Average Price Target€36.84Lowest Price Target€26.04
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on DE:C6K0
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
€30.38→€26.04
Buy
68.41%
Upside
Reiterated
08/07/26
Avalo Therapeutics price target lowered to $30 from $35 at H.C. WainwrightAvalo Therapeutics price target lowered to $30 from $35 at H.C. Wainwright
Bank of America Securities Analyst forecast on DE:C6K0
Alec Stranahan
Bank of America Securities
Bank of America Securities
€30.38
Buy
96.48%
Upside
Reiterated
08/07/26
Bank of America Securities Reaffirms Their Buy Rating on Avalo Therapeutics (AVTX)
BTIG Analyst forecast on DE:C6K0
Julian Harrison
BTIG
BTIG
€50.34
Buy
225.60%
Upside
Reiterated
08/06/26
Avalo Therapeutics (AVTX) Gets a Buy from BTIG
Guggenheim Analyst forecast on DE:C6K0
Yatin Suneja
Guggenheim
Guggenheim
€43.39→€41.66
Buy
169.46%
Upside
Reiterated
08/06/26
Avalo Therapeutics price target lowered to $48 from $50 at GuggenheimAvalo Therapeutics price target lowered to $48 from $50 at Guggenheim
Leerink Partners Analyst forecast on DE:C6K0
Thomas Smith
Leerink Partners
Leerink Partners
€32.98
Buy
113.32%
Upside
Initiated
07/06/26
Avalo Therapeutics initiated with an Outperform at LeerinkAvalo Therapeutics initiated with an Outperform at Leerink
TD Cowen Analyst forecast on DE:C6K0
Stacy Ku
TD Cowen
TD Cowen
―
Buy
―
Reiterated
06/11/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Stifel Nicolaus Analyst forecast on DE:C6K0
Alex Thompson CFA
Stifel Nicolaus
Stifel Nicolaus
€31.24→€33.85
Buy
118.93%
Upside
Reiterated
05/15/26
Analysts Offer Insights on Healthcare Companies: Avalo Therapeutics (NASDAQ: AVTX) and Immunic (NASDAQ: IMUX)
Citizens JMP Analyst forecast on DE:C6K0
Jason Butler
Citizens JMP
Citizens JMP
€53.81→€47.73
Buy
208.75%
Upside
Reiterated
05/14/26
Avalo Therapeutics price target lowered to $55 from $62 at CitizensAvalo Therapeutics price target lowered to $55 from $62 at Citizens
Mizuho Securities Analyst forecast on DE:C6K0
Joseph Catanzaro
Mizuho Securities
Mizuho Securities
€33.85→€39.05
Buy
152.62%
Upside
Reiterated
05/14/26
Avalo Therapeutics price target raised to $45 from $39 at MizuhoAvalo Therapeutics price target raised to $45 from $39 at Mizuho
Wedbush Analyst forecast on DE:C6K0
Robert Driscoll
Wedbush
Wedbush
€34.72→€29.51
Buy
90.87%
Upside
Reiterated
05/14/26
Avalo Therapeutics price target lowered to $34 from $40 at WedbushAvalo Therapeutics price target lowered to $34 from $40 at Wedbush
Piper Sandler Analyst forecast on DE:C6K0
Yasmeen Rahimi
Piper Sandler
Piper Sandler
€41.66→€52.07
Buy
236.82%
Upside
Assigned
05/11/26
Avalo Therapeutics price target raised to $60 from $48 at Piper SandlerAvalo Therapeutics price target raised to $60 from $48 at Piper Sandler
Wolfe Research Analyst forecast on DE:C6K0
Andy Chen
Wolfe Research
Wolfe Research
€41.66
Buy
169.46%
Upside
Initiated
04/08/26
Avalo Therapeutics initiated with an Outperform at Wolfe ResearchAvalo Therapeutics initiated with an Outperform at Wolfe Research
Oppenheimer Analyst forecast on DE:C6K0
Leland Gershell
Oppenheimer
Oppenheimer
€30.38
Buy
96.48%
Upside
Reiterated
09/29/25
Oppenheimer Remains a Buy on Avalo Therapeutics (AVTX)
Cantor Fitzgerald Analyst forecast on DE:C6K0
Prakhar Agrawal
Cantor Fitzgerald
Cantor Fitzgerald
―
Buy
―
Initiated
08/15/25
Avalo Therapeutics initiated with an Overweight at Cantor FitzgeraldAvalo Therapeutics initiated with an Overweight at Cantor Fitzgerald
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on DE:C6K0
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
€30.38→€26.04
Buy
68.41%
Upside
Reiterated
08/07/26
Avalo Therapeutics price target lowered to $30 from $35 at H.C. WainwrightAvalo Therapeutics price target lowered to $30 from $35 at H.C. Wainwright
Bank of America Securities Analyst forecast on DE:C6K0
Alec Stranahan
Bank of America Securities
Bank of America Securities
€30.38
Buy
96.48%
Upside
Reiterated
08/07/26
Bank of America Securities Reaffirms Their Buy Rating on Avalo Therapeutics (AVTX)
BTIG Analyst forecast on DE:C6K0
Julian Harrison
BTIG
BTIG
€50.34
Buy
225.60%
Upside
Reiterated
08/06/26
Avalo Therapeutics (AVTX) Gets a Buy from BTIG
Guggenheim Analyst forecast on DE:C6K0
Yatin Suneja
Guggenheim
Guggenheim
€43.39→€41.66
Buy
169.46%
Upside
Reiterated
08/06/26
Avalo Therapeutics price target lowered to $48 from $50 at GuggenheimAvalo Therapeutics price target lowered to $48 from $50 at Guggenheim
Leerink Partners Analyst forecast on DE:C6K0
Thomas Smith
Leerink Partners
Leerink Partners
€32.98
Buy
113.32%
Upside
Initiated
07/06/26
Avalo Therapeutics initiated with an Outperform at LeerinkAvalo Therapeutics initiated with an Outperform at Leerink
TD Cowen Analyst forecast on DE:C6K0
Stacy Ku
TD Cowen
TD Cowen
―
Buy
―
Reiterated
06/11/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Stifel Nicolaus Analyst forecast on DE:C6K0
Alex Thompson CFA
Stifel Nicolaus
Stifel Nicolaus
€31.24→€33.85
Buy
118.93%
Upside
Reiterated
05/15/26
Analysts Offer Insights on Healthcare Companies: Avalo Therapeutics (NASDAQ: AVTX) and Immunic (NASDAQ: IMUX)
Citizens JMP Analyst forecast on DE:C6K0
Jason Butler
Citizens JMP
Citizens JMP
€53.81→€47.73
Buy
208.75%
Upside
Reiterated
05/14/26
Avalo Therapeutics price target lowered to $55 from $62 at CitizensAvalo Therapeutics price target lowered to $55 from $62 at Citizens
Mizuho Securities Analyst forecast on DE:C6K0
Joseph Catanzaro
Mizuho Securities
Mizuho Securities
€33.85→€39.05
Buy
152.62%
Upside
Reiterated
05/14/26
Avalo Therapeutics price target raised to $45 from $39 at MizuhoAvalo Therapeutics price target raised to $45 from $39 at Mizuho
Wedbush Analyst forecast on DE:C6K0
Robert Driscoll
Wedbush
Wedbush
€34.72→€29.51
Buy
90.87%
Upside
Reiterated
05/14/26
Avalo Therapeutics price target lowered to $34 from $40 at WedbushAvalo Therapeutics price target lowered to $34 from $40 at Wedbush
Piper Sandler Analyst forecast on DE:C6K0
Yasmeen Rahimi
Piper Sandler
Piper Sandler
€41.66→€52.07
Buy
236.82%
Upside
Assigned
05/11/26
Avalo Therapeutics price target raised to $60 from $48 at Piper SandlerAvalo Therapeutics price target raised to $60 from $48 at Piper Sandler
Wolfe Research Analyst forecast on DE:C6K0
Andy Chen
Wolfe Research
Wolfe Research
€41.66
Buy
169.46%
Upside
Initiated
04/08/26
Avalo Therapeutics initiated with an Outperform at Wolfe ResearchAvalo Therapeutics initiated with an Outperform at Wolfe Research
Oppenheimer Analyst forecast on DE:C6K0
Leland Gershell
Oppenheimer
Oppenheimer
€30.38
Buy
96.48%
Upside
Reiterated
09/29/25
Oppenheimer Remains a Buy on Avalo Therapeutics (AVTX)
Cantor Fitzgerald Analyst forecast on DE:C6K0
Prakhar Agrawal
Cantor Fitzgerald
Cantor Fitzgerald
―
Buy
―
Initiated
08/15/25
Avalo Therapeutics initiated with an Overweight at Cantor FitzgeraldAvalo Therapeutics initiated with an Overweight at Cantor Fitzgerald
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
BTSGBrightSpring Health Services, Inc.
AMLXAmylyx Pharmaceuticals Inc
IMMXImmix Biopharma
TNYATenaya Therapeutics
JBIOJade Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Avalo Therapeutics

3 Months
Julian HarrisonBTIG
Success Rate
5/8 ratings generated profit
63%
Average Return
+26.90%
Copying Julian Harrison's trades and holding each position for 3 Months would result in 62.50% of your transactions generating a profit, with an average return of +26.90% per trade.
1 Year
Julian HarrisonBTIG
Success Rate
7/8 ratings generated profit
88%
Average Return
+81.29%
Copying Julian Harrison's trades and holding each position for 1 Year would result in 87.50% of your transactions generating a profit, with an average return of +81.29% per trade.
2 Years
Julian HarrisonBTIG
Success Rate
7/8 ratings generated profit
88%
Average Return
+90.76%
Copying Julian Harrison's trades and holding each position for 2 Years would result in 87.50% of your transactions generating a profit, with an average return of +90.76% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

C6K0 Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
12
21
15
13
6
Buy
0
0
1
1
1
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
12
21
16
14
7
In the current month, C6K0 has received 7 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. C6K0 average Analyst price target in the past 3 months is 36.84.
Each month's total comprises the sum of three months' worth of ratings.

C6K0 Financial Forecast

C6K0 Earnings Forecast

Next quarter’s earnings estimate for C6K0 is -€0.49 with a range of -€0.85 to -€0.19. The previous quarter’s EPS was -€0.72. C6K0 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 58.33% of the time in the same period. In the last calendar year C6K0 has Performed in-line its overall industry.
Next quarter’s earnings estimate for C6K0 is -€0.49 with a range of -€0.85 to -€0.19. The previous quarter’s EPS was -€0.72. C6K0 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 58.33% of the time in the same period. In the last calendar year C6K0 has Performed in-line its overall industry.

C6K0 Sales Forecast

Next quarter’s sales forecast for C6K0 is €0.00 with a range of €0.00 to €0.00. The previous quarter’s sales results were €0.00. C6K0 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 66.67% of the time in the same period. In the last calendar year C6K0 has Performed in-line its overall industry.
Next quarter’s sales forecast for C6K0 is €0.00 with a range of €0.00 to €0.00. The previous quarter’s sales results were €0.00. C6K0 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 66.67% of the time in the same period. In the last calendar year C6K0 has Performed in-line its overall industry.

C6K0 Stock Forecast FAQ

What is DE:C6K0’s average 12-month price target, according to analysts?
Based on analyst ratings, Avalo Therapeutics’s 12-month average price target is 36.84.
    What is DE:C6K0’s upside potential, based on the analysts’ average price target?
    Avalo Therapeutics has 138.27% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Avalo Therapeutics a Buy, Sell or Hold?
          Avalo Therapeutics has a consensus rating of Strong Buy, which is based on 10 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Avalo Therapeutics’s share price target?
            The average share price target for Avalo Therapeutics is 36.84. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €50.34 ,and the lowest forecast is €26.04. The average share price target represents 138.27% Increase from the current price of €15.46.
              What do analysts say about Avalo Therapeutics?
              Avalo Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.
                How can I buy shares of Avalo Therapeutics?
                To buy shares of DE:C6K0, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.